Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches

mAbs

Volumn 5, Issue 6, 2013, Pages 962-973

  Gramer, Michael J ^b,d   Van Den Bremer, Ewald T J ^a   Van Kampen, Muriel D ^a   Kundu, Amitava ^b,d   Kopfmann, Peter ^b,d   Etter, Eric ^b,d   Stinehelfer, David ^b,d   Long, Justin ^b,d   Lannom, Tom ^b,d   Noordergraaf, Esther H ^a   Gerritsen, Jolanda ^a   Labrijn, Aran F ^a   Schuurman, Janine ^a   Van Berkel, Patrick H C ^a,c   Parren, P Whi ^a  

^a GENMAB   (Netherlands)

^b Genmab   (United States)

^c ADC Therapeutics   (Switzerland)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bispecific antibodies; Cell culture; Controlled Fab arm exchange; Large scale manufacturing; Purification; Scale up

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CATION EXCHANGE; CHEMICAL PROCEDURES; DIAFILTRATION; DISULFIDE BOND; ELECTROSPRAY MASS SPECTROMETRY; FAB ARM EXCHANGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PURIFICATION; ANIMAL; BIOREACTOR; BIOSYNTHESIS; CHO CELL LINE; CRICETULUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HAMSTER; PROTEIN ENGINEERING; PROTEIN STABILITY;

ANIMALS; ANTIBODIES, BISPECIFIC; BIOREACTORS; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; POINT MUTATION; PROTEIN ENGINEERING; PROTEIN STABILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84889831910     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26233     Document Type: Article

References (34)

1. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009; 1:443-52; PMID:20065641; http://dx.doi.org/10.4161/mabs.1.5.9448
2. Shukla AA, Thömmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 2010; 28:253-61; PMID:20304511; http://dx.doi.org/10.1016/j.tibtech.2010.02.001
3. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
4. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772; http://dx.doi.org/10.1038/305537a0
5. Cook AG, Wood PJ. Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems. J Immunol Methods 1994; 171:227-37; PMID:8195590; http://dx.doi.org/10.1016/0022-1759(94)90042-6
6. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
7. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
8. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
9. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
10. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
11. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
12. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
13. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; http://dx.doi.org/10. 1158/0008-5472.CAN-09-0547
14. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672-92; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
15. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
16. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23:115-27; PMID:20022918; http://dx.doi.org/10.1093/protein/gzp073
17. De Bernardis F, Liu H, O'Mahony R, La Valle R, Bartollino S, Sandini S, Grant S, Brewis N, Tomlinson I, Basset RC, et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007; 195:149-57; PMID:17152019; http://dx.doi.org/10.1086/509891
18. Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007; 318:65-74; PMID:17126853; http://dx.doi.org/10.1016/j.jim.2006.09.020
19. Chames P, Baty D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 2009; 12:276-83; PMID:19333873
20. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
21. Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22:238-44; PMID:15109810; http://dx.doi.org/10.1016/j.tibtech.2004.03.006
22. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
23. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas. 1220145110
24. Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol 2011; 187:3238-46; PMID:21841137; http://dx.doi.org/10.4049/jimmunol.1003336
25. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-800; PMID:15172969; http://dx.doi.org/10.1182/ blood-2004-01-0039
26. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173:4699-707; PMID:15383606
27. Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, et al. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs 2013; 5:219-28; PMID:23255090
28. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007
29. Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ET, Gerritsen J, van Berkel PH. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 2011; 108:1591-602; PMID:21328321; http://dx.doi.org/10.1002/ bit.23075
30. Hawe A, Kasper JC, Friess W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 2009; 38:79-87; PMID:19540340; http://dx.doi.org/10.1016/j.ejps. 2009.06.001
31. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 2009; 98:3509-21; PMID:19475547; http://dx.doi.org/10. 1002/jps.21655
32. Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19:1274-82; PMID:21893287; http://dx.doi.org/10.1016/j.str.2011.06.016
33. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
34. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt. 1553